This is supported by the absence of pyroptosis-related markers in BRAF and MEK-combined inhibition-resistant BRAF-mutant cancer models, which was associated with reduced T cell antitumor immunity and, importantly, was sensitive to pyroptosis-inducing chemotherapy [152]. The gene discussed is MAP2K7; the disease is cancer.